Advanced Search:
Equity Index Forex Crypto Commodity

SLP - Simulations Plus

$45.35  -0.1 (-0.22%)

Updated: 01:55 May 1, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

Simulations Plus's Position Within the Health Information Services Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

SIMULATIONS PLUS - HISTORICAL DATA 6M

  • Last price

    $ 45.35

  • Daily change

    $ -0.1

  • Previous Close

    $ 45.45

  • Last Updated

    01:55 May 1, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.42 0.2 0.23 0.03

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 1.5 2.39 1.99 1.9

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A 0% 27.33% 56.15%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 45.54 1.88% 44.7 8.84% 41.07

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.01 39.76 0.58 50.25

Simulations Plus Technical Analysis News

Simulations Plus

42505 Tenth Street West
Lancaster, CA 93534-7059
United States
661 723 7723
http://www.simulations-plus.com

Sectors: Healthcare
Industry: Health Information Services
F. Time Employees: 129
Description

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.

Corporate Governance

Simulations Plus, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 5. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 1; Compensation: 5.

SIMULATIONS PLUS'S HOLDERS RANK

List of holders with stock participation in Simulations Plus.

Holder Rank Holder Shares Date Reported % Out Value